Rhythm Pharmaceuticals

Rhythm is a commercial-stage biopharmaceutical company dedicated to transforming the treatment of people with rare genetic disorders of obesity. The company’s precision medicine, IMCIVREE™ (setmelanotide), has received FDA approval for chronic weight management in adult and pediatric patients aged 6 years and older with obesity due to genetically confirmed POMC, PCSK1, or LEPR deficiencies. IMCIVREE is the first FDA-approved therapy for the treatment of these rare genetic disorders of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic disorders of obesity. The company is leveraging the Rhythm Engine and the largest known DNA database of obesity, which now includes approximately 37,500 sequenced samples, to enhance understanding, diagnosis, and care for individuals with severe obesity caused by certain genetic defects.